AstraZeneca reports profit growth, supported by oncology drugs

The net profit of pharmaceutical giant AstraZeneca increased by over 2% to $2.51 billion (approximately €2.2 billion) during the quarter ending in June. The main driver for the financial result is stable growth in the oncology and rare disease treatment segments.

Financial Indicators and Market Reaction

The company's total revenue reached $15.38 billion (€13.49 billion), representing a 5% increase at constant exchange rates. Core earnings per share reached $2.63—an 18% increase at constant exchange rates, which is higher than the $2.48 predicted by analysts.

The market reacted positively to the reports, with the company's shares noting a 1.4% increase at the start of European trading. This follows an earlier decline in early July, caused by the failure of the drug Wainua to meet set goals in a clinical trial.

Strategic Goals and New Developments

AstraZeneca CEO Pascal Soriot emphasized that the company continues to strive toward its goal of achieving $80 billion in total revenue by 2030. Despite the failure of one of the trials, Soriot expressed confidence in the product pipeline, adding that over 20 important clinical trial results are expected over the next 18 months.

Parallel to oncology, AstraZeneca is developing treatments for obesity. Data from June shows that the experimental weight-loss pill elecoglipron leads to an average weight loss of 10.5% after 26 weeks and 11.8% after 36 weeks at the highest dose. The success of these trials would allow the company to compete in the weight-loss drug market, which is currently dominated by Novo Nordisk and Eli Lilly.